Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dovramilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 0.59 |
| ▸ | PDE4C known ✓ | Q08493 | 18/20 | 0.59 |
| ▸ | PDE4A known ✓ | P27815 | 12/20 | 0.59 |
| ▸ | PDE4D known ✓ | Q08499 | 12/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dovramilast SCHEMBL673303 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL30701938 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869364 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL14983202 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL29366888 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869363 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869345 | 0.95 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869344 | 0.95 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15580958 | 0.95 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869347 | 0.94 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | claimed |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION | 2016-10-06 | — | — | US | claimed |
| EP-3065778-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2016-09-14 | — | — | EP | claimed |
| WO-2015069711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-05-14 | — | — | WO | claimed |
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2013-05-30 | — | — | US | claimed |
| WO-2011127019-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2011-10-13 | — | — | WO | claimed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-3899539-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3827836-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | Celgene Corporation (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020132189-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | ORIONIS BIOSCIENCES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-2765993-B1 | FORMULATIONS OF CYCLOPROPANECARBOXYLIC ACID {2-[(1S)-1-(3-ETHOXY-4-METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-3-OXO-2, 3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | AMGEN EUROPE GMBH (CH) | 2020-05-20 | — | — | EP | disclosed |
| WO-2006050057-A2 | METHODS AND COMPOSITIONS USING PDE4 MODULATORS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM INJURY | CELGENE CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060035955-A1 | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | CELGENE CORPORATION | 2006-02-16 | — | — | US | disclosed |
| US-20060035955-A1 | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | CELGENE CORPORATION | 2006-02-16 | — | — | US | disclosed |
| WO-2005112917-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005102317-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2004080393-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004034962-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | PDE4A, PDE4B, IL4 | PDE4B 2/4885PDE4C 4/4885PDE4A 1/4885 |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20060035955-A1 | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | IL2, HDGF, TNF | PDE4B 580/4885PDE4C 558/4885PDE4A 741/4885 |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.